Genentech cancer drug Phase III trial meets primary endpoint
The results of the trial demonstrated that patients with HER2-positive metastatic breast cancer (mBC) who have been administered combined medicine of pertuzumab and Herceptin (trastuzumab), in addition to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.